Treatment Options in Alzheimer’s Disease: Maximizing Benefit, Managing Expectations
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is becoming an increasingly heavy burden on the society of developed countries, and physicians now face the challenge of providing efficient treatment regimens to an ever-higher number of individuals affected by the disease. Currently approved anti-AD therapies – the cholinesterase inhibitors and the N-methyl-D-aspartate receptor antagonist memantine – offer modest symptomatic relief, which can be enhanced using combination therapy with both classes of drugs. Additionally, alternative therapies such as nonsteroidal anti-inflammatory drugs, vitamin E, selegiline, Ginkgo biloba extracts, estrogens, and statins, as well as behavioral and lifestyle changes, have been explored as therapeutic options. Until a therapy is developed that can prevent or reverse the disease, the optimal goal for effective AD management is to develop a treatment regimen that will yield maximum benefits for individual patients across multiple domains, including cognition, daily functioning, and behavior, and to provide realistic expectations for patients and caregivers throughout the course of the disease. This review provides a basic overview of approved AD therapies, discusses some pharmacologic and nonpharmacologic treatment strategies that are currently being investigated, and offers suggestions for optimizing treatment to fit the needs of individual patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Current concepts in mild cognitive impairment
Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.1985 · Cited by 4,781
Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality
Miller, E. R., Pastor-Barriuso, R., Dalal, D., Riemersma, R. A., Appel, L. J., & Guallar, E. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-1-200501040-00110 · Cited by 2,577
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168 · cited 1×
“Alzheimer’s disease (AD) is the most common cause of dementia in the elderly, affecting approximately 4.5 million people in the United States alone [”
BackgroundInfluentialMemantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Leisure Activities and the Risk of Dementia in the Elderly
Verghese, J., Lipton, R. B., Katz, M. J., Hall, C. B., Derby, C. A., Kuslansky, G., Ambrose, A. F., Sliwinski, M., & Buschke, H. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022252 · Cited by 1,961
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease
Gómez-Isla, T., Price, J. L., McKeel Jr., D. W., Morris, J. C., Growdon, J. H., & Hyman, B. T. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-14-04491.1996 · Cited by 1,796 · cited 1×
“Maximizing BenefitUltimately, the hope for a truly revolutionary AD therapy lies in the potential of some pipeline compound to prevent or delay the onset of the disease. Until this possibility is realized, it is important that practicing physicians optimize available symptomatic therapies in order to provide the best…”
BackgroundLarson, E. B., Wang, L., Bowen, J. D., McCormick, W. C., Teri, L., Crane, P., & Kukull, W. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-2-200601170-00004 · Cited by 1,463
Lindsay, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf074 · Cited by 1,261
Heyn, P., Abreu, B. C., & Ottenbacher, K. J. (2004) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2004.03.019 · Cited by 1,223
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
Physical Activity, Including Walking, and Cognitive Function in Older Women
Weuve, J. (2004) · JAMA · doi:10.1001/jama.292.12.1454 · Cited by 1,175
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
Consumption of Fish and n-3 Fatty Acids and Risk of Incident Alzheimer Disease
Morris, M. C., Evans, D. A., Bienias, J. L., Tangney, C. C., Bennett, D. A., Wilson, R. S., Aggarwal, N., & Schneider, J. (2003) · Archives of Neurology · doi:10.1001/archneur.60.7.940 · Cited by 1,135
Postmenopausal Hormone Replacement Therapy: Scientific Review
Nelson, H. D., Humphrey, L. L., Nygren, P., Teutsch, S. M., & Allan, J. D. (2002) · JAMA · doi:10.1001/jama.288.7.872 · Cited by 990 · cited 1×
“Observational studies have revealed a lower incidence of AD in postmenopausal women taking estrogen, suggesting that estrogen may have a protective role in AD [”
BackgroundRosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond
Lipton, S. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1958 · Cited by 909 · cited 1×
“Preclinical studies with memantine are consistent with a putative neuroprotective role [”
ResultRaskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
Walking and Dementia in Physically Capable Elderly Men
Abbott, R. D. (2004) · JAMA · doi:10.1001/jama.292.12.1447 · Cited by 743 · cited 1×
“In addition, regular physical activity has been associated with the maintenance of healthy brain function, increased neuronal survival, protection against neuronal injury, and a reduced risk of dementia in cognitively normal elderly persons [ , ,”
BackgroundTariq, S. H., Tumosa, N., Chibnall, J. T., Perry, M. H., & Morley, J. E. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000221510.33817.86 · Cited by 724
Rezai-Zadeh, K., Shytle, D., Sun, N., Mori, T., Hou, H., Jeanniton, D., Ehrhart, J., Townsend, K., Zeng, J., Morgan, D., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1521-05.2005 · Cited by 713
Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain
Ingelsson, M., Fukumoto, H., Newell, K. L., Growdon, J. H., Hedley–Whyte, E. T., Frosch, M. P., Albert, M. S., Hyman, B. T., & Irizarry, M. C. (2004) · Neurology · doi:10.1212/01.wnl.0000115115.98960.37 · Cited by 666
Morris, J. C., Storandt, M., McKeel, D. W., Rubin, E. H., Price, J. L., Grant, E. A., & Berg, L. (1996) · Neurology · doi:10.1212/wnl.46.3.707 · Cited by 603
Improving caregiver well-being delays nursing home placement of patients with Alzheimer disease
Mittelman, M. S., Haley, W. E., Clay, O. J., & Roth, D. L. (2006) · Neurology · doi:10.1212/01.wnl.0000242727.81172.91 · Cited by 602 · cited 1×
“Therefore, patients should be encouraged to maintain or initiate healthy lifestyles, including a balanced diet, increased mental and physical activities, and regular social contact with peers and family members.Finally, since patients with AD become increasingly dependent on caregiver support as the disease progresses…”
BackgroundRivastigmine for Alzheimer’s disease.
Birks, J. S., Chong, L.-Y., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub4 · Cited by 534
Conversion from subtypes of mild cognitive impairment to Alzheimer dementia
Fischer, P., Jungwirth, S., Zehetmayer, S., Weissgram, S., Hoenigschnabl, S., Gelpi, E., Krampla, W., & Tragl, K. H. (2007) · Neurology · doi:10.1212/01.wnl.0000252358.03285.9d · Cited by 471
Annual Incidence of Alzheimer Disease in the United States Projected to the Years 2000 Through 2050
Hebert, L. E., Beckett, L. A., Scherr, P. A., & Evans, D. A. (2001) · Alzheimer Disease and Associated Disorders · doi:10.1097/00002093-200110000-00002 · Cited by 467
Body Mass Index in Midlife and Risk of Alzheimer Disease and Vascular Dementia
Whitmer, R., Gunderson, E., Quesenberry, C., Zhou, J., & Yaffe, K. (2007) · Current Alzheimer Research · doi:10.2174/156720507780362047 · Cited by 430
Fish Consumption and Cognitive Decline With Age in a Large Community Study
Morris, M. C., Evans, D. A., Tangney, C. C., Bienias, J. L., & Wilson, R. S. (2005) · Archives of Neurology · doi:10.1001/archneur.62.12.noc50161 · Cited by 428
Antioxidant Vitamin Intake and Risk of Alzheimer Disease
Luchsinger, J. A., Tang, M.-X., Shea, S., & Mayeux, R. (2003) · Archives of Neurology · doi:10.1001/archneur.60.2.203 · Cited by 414
A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment
on behalf of the Rofecoxib Protocol 078 study group, Thal, L. J., Ferris, S. H., Kirby, L., Block, G. A., Lines, C. R., Yuen, E., Assaid, C., Nessly, M. L., Norman, B. A., et al. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300690 · Cited by 402
Dementia care: mental health effects, intervention strategies, and clinical implications
Sörensen, S., Duberstein, P., Gill, D., & Pinquart, M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70599-3 · Cited by 396 · cited 1×
“Caregivers should be directed to educational and support resources, such as the Alzheimer’s Association website (http://www.alz.org), which contains a large amount of information about local resources, caregiver support, and patient care. The issue of caregiver burden has been largely overlooked until recently, and de…”
BackgroundClinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors
Jann, M. W., Shirley, K. L., & Small, G. W. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241100-00003 · Cited by 365 · cited 1×
“As with other ChEIs, gastrointestinal side effects associated with rivastigmine are common (vomiting, nausea, diarrhea, anorexia, abdominal pain; table 2 ), but some can be circumvented using a slower dose-titration scheme, upwardly titrating monthly rather than every 2 weeks [”
BackgroundDoody, R. S. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.427 · Cited by 362 · cited 1×
“As cognitive and behavioral methods pose little risk to patients and caregivers, and may provide benefits, caregivers should be encouraged to pursue these alternative strategies if desired. However, more rigorously controlled long-term studies will be required to determine which of these techniques, if any, can provid…”
BackgroundEvidence-based psychological treatments for distress in family caregivers of older adults.
Gallagher-Thompson, D., & Coon, D. W. (2007) · Psychology and Aging · doi:10.1037/0882-7974.22.1.37 · Cited by 358
Vitamin E and Vitamin C Supplement Use and Risk of Incident Alzheimer Disease
Morris, M. C., Beckett, L. A., Scherr, P. A., Hebert, L. E., Bennett, D. A., Field, T. S., & Evans, D. A. (1998) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199809000-00001 · Cited by 332
Trinh, N.-H., Hoblyn, J., Mohanty, S., & Yaffe, K. (2003) · JAMA · doi:10.1001/jama.289.2.210 · Cited by 37
Belle, S. H., Burgio, L., Burns, R., Coon, D., Czaja, S. J., Gallagher-Thompson, D., Gitlin, L. N., Klinger, J., Koepke, K. M., Lee, C. C., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-10-200611210-00005 · Cited by 23
Procedures for identifying evidence-based psychological treatments for older adults
Yon, A., & Scogin, F. (2007) · Psychology and Aging · doi:10.1037/0882-7974.22.1.4 · Cited by 23 · cited 1×
“although this has not been clinically verified. Future studies are expected to clarify the role of cholesterol and cholesterol-processing pathways on AD progression and to ascertain whether the putative effects of statins in AD are related to their lipid-lowering properties. Regardless of age or risk of dementia, all…”
BackgroundAisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., Thal, L. J., et al. (2003) · JAMA · doi:10.1001/jama.289.21.2819 · Cited by 5
Self-citation
Cited by
A review on Alzheimer's disease pathophysiology and its management: an update
Kumar, A., Singh, A., & Ekavali (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.09.004 · Cited by 1,578
Alzheimer’s Disease: The Challenge of the Second Century
Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002369 · Cited by 1,424
Chemical analysis and quality control of Ginkgo biloba leaves, extracts, and phytopharmaceuticals
van Beek, T. A., & Montoro, P. (2009) · Journal of Chromatography A · doi:10.1016/j.chroma.2009.01.013 · Cited by 550
Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
M. de la Monte, S. (2012) · Current Alzheimer Research · doi:10.2174/156720512799015037 · Cited by 448
León, R., Garcia, A. G., & Marco‐Contelles, J. (2013) · Medicinal Research Reviews · doi:10.1002/med.20248 · Cited by 440
Metadata
- Authors
- Farlow, M. R., Miller, M. L., & Pejovic, V.
- Venue
- Dementia and Geriatric Cognitive Disorders
- Publisher
- S. Karger AG
- Published
- 2008
- Volume
- 25
- Issue
- 5
- Pages
- 408-422
- ISSN
- 1420-8008 (ISSN-L)
- 1421-9824
- OpenAlex
- W2035463674
- Cited by
- 129
- References
- 46
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.